Another big year beckons for biotech venture financing
Private drug developers have already raised more money this year than in 2020.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Medtech venture backers go in early
A sudden increase in seed and series A funding bodes well for the year ahead.
Europe’s venture boom trails the US
But financing sizes have grown by a similar amount on both sides of the Atlantic.
The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Biotech venture financing starts the year with a bang
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
